Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002)

被引：0

作者：

Katakami, Nobuyuki ^{[1
,2
,3
]}

Nagata, Kazuma ^{[2
,3
]}

Nakakura, Akiyoshi ^{[4
]}

Okamoto, Tadashi ^{[1
,2
,3
]}

Kaneda, Toshihiko ^{[5
]}

Oki, Masahide ^{[6
]}

Watanabe, Kana ^{[7
]}

Tokito, Takaaki ^{[8
]}

Amano, Yoshihiro ^{[9
]}

Tamiya, Motohiro ^{[10
]}

Morita, Satoshi ^{[4
]}

Hatachi, Yukimasa ^{[1
]}

机构：

[1] Takarazuka City Hosp, Divison Med Oncol Pulm Med, Takarazuka, Japan

[2] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Japan

[3] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Japan

[4] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan

[5] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Japan

[6] Natl Hosp Org, Nagoya Med Ctr, Dept Resp Med, Nagoya, Japan

[7] Miyagi Canc Ctr, Dept Resp Med, Natori, Japan

[8] Kurume Univ, Dept Respirol Neurol & Rheumatol, Sch Med, Kurume, Japan

[9] Shimane Univ, Sch Med, Dept Resp Med, Izumo, Japan

[10] Osaka Habikino Med Ctr, Dept Thorac Malignancy, Habikino, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 55卷 / 01期

关键词：

idiopathic interstitial pneumonia; non-small cell non-squamous cell lung cancer; phase II study; chemotherapy; bevacizumab; PULMONARY-FIBROSIS; ELDERLY-PATIENTS; STAGE-IIIB; COMBINATION; EFFICACY; DISEASE; SAFETY; TRIAL; EXACERBATION; CHEMOTHERAPY;

D O I：

10.1093/jjco/hyae132

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background There is an increased risk of acute exacerbation of idiopathic interstitial pneumonia when treating patients with advanced non-small cell lung cancer with idiopathic interstitial pneumonia. There is no standard optimal treatment regimen for patients with lung cancer complicated with idiopathic interstitial pneumonia. We aimed to evaluate the efficacy and safety of carboplatin (CBDCA), bevacizumab (Bmab) and weekly paclitaxel (PXT) in patients with idiopathic interstitial pneumonia.Methods This phase 2 study involved chemotherapy-na & iuml;ve patients with advanced non-small cell lung cancer with idiopathic interstitial pneumonia. Patients received CBDCA (area under the curve: 5 on day 1), PXT (70 mg/m2 on days 1, 8 and 15) and Bmab (15 mg/kg on day 1) every 4 weeks. The primary endpoint was the overall response rate.Results Twenty-one patients were enrolled between January 2013 and October 2018 and received at least one course of the protocol treatment. The study was terminated before enrolling the planned number of patients because of poor accrual. The median patient age was 69 (range: 62-79) years, and 19 (90.5%) patients were men. The overall response rate was 61.9% (95% confidence interval [CI], 38.4-81.9), meeting the primary endpoint. The median progression-free survival, time to treatment failure, and overall survival were 9.69 (95% CI, 5.78-11.63), 8.21 (95% CI, 3.75-11.63) and 20.93 (95% CI, 13.17-29.83) months, respectively. There was no acute exacerbation or treatment-related death during protocol treatment.Conclusion The results indicate that patients with advanced non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia could be effectively and safely treated using a combination of CBDCA, PXT and Bmab. Patients with advanced nonsquamous, non-small cell lung cancer with idiopathic interstitial pneumonia could be effectively and safely treated using a combination of CBDCA, PXT and Bmab.

引用

页码：67 / 74

页数：8

共 39 条

[1] The associations of interstitial lung abnormalities with cancer diagnoses and mortality [J].

Axelsson, Gisli T. ;

Putman, Rachel K. ;

Aspelund, Thor ;

Gudmundsson, Elias F. ;

Hida, Tomayuki ;

Araki, Tetsuro ;

Nishino, Mizuki ;

Hatabu, Hiroto ;

Gudnason, Vilmundur ;

Hunninghake, Gary M. ;

Gudmundsson, Gunnar .

EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (06)

[2] Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients [J].

Azuma, Arata ;

Hagiwara, Koichi ;

Kudoh, Shoji .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (12) :1397-1398

[3] Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer [J].

Belani, Chandra P. ;

Ramalingam, Suresh ;

Perry, Michael C. ;

LaRocca, Renato V. ;

Rinaldi, David ;

Gable, Preston S. ;

Tester, William J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :468-473

[4] Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation [J].

Belani, CP ;

Barstis, J ;

Perry, MC ;

La Rocca, RV ;

Nattam, SR ;

Rinaldi, D ;

Clark, R ;

Mills, GM .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2933-2939

[5] Idiopathic Pulmonary Fibrosis and Lung Cancer A Systematic Review and Meta-analysis [J].

Brown, Stacey-Ann Whittaker ;

Dobelle, Molly ;

Padilla, Maria ;

Agovino, Mariangela ;

Wisnivesky, Juan P. ;

Hashim, Dana ;

Boffetta, Paolo .

ANNALS OF THE AMERICAN THORACIC SOCIETY, 2019, 16 (08) :1041-1051

[6] The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review [J].

Chen, Yu Jie ;

Chen, Ling Xiao ;

Han, Mei Xiang ;

Zhang, Tian Song ;

Zhou, Zhi Rui ;

Zhong, Dian Sheng .

MEDICINE, 2015, 94 (36)

[7]

Enomoto Y, 2015, ANTICANCER RES, V35, P4259

[8] Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study [J].

Fukuizumi, Aya ;

Minegishi, Yuji ;

Omori, Miwako ;

Atsumi, Kenichiro ;

Takano, Natsuki ;

Hisakane, Kakeru ;

Takahashi, Satoshi ;

Kobayashi, Kenichi ;

Sugano, Teppei ;

Takeuchi, Susumu ;

Noro, Rintaro ;

Seike, Masahiro ;

Kubota, Kaoru ;

Azuma, Arata ;

Gemma, Akihiko .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (12) :1543-1548

[9]

Gemma A, 2006, ANTICANCER RES, V26, P3083

[10] Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice [J].

Hamada, N ;

Kuwano, K ;

Yamada, M ;

Hagimoto, N ;

Hiasa, K ;

Egashira, K ;

Nakashima, N ;

Maeyama, T ;

Yoshimi, M ;

Nakanishi, Y .

JOURNAL OF IMMUNOLOGY, 2005, 175 (02) :1224-1231

← 1 2 3 4 →